However, novel drugs such as tyrosine kinase inhibitors (TKI), MoAbs-directed against CD19, CD20, and CD22 and drugs interfering with the overexpression of genes involved in tumor survival offer opportunities to personalize therapy on the basis of clinical characteristics and organ fitness of the patient.1 With promising results, the transition toward personalized treatment appears to be underway. This evidence concerns the gene CD19 and neoplasm.